Hospital AI Lab Practical information on medical AI for U.S. hospitals

Updated:

FDA Rule on MCI Prognosis Software: What Hospitals Check

What does FDA's new class II rule for mild cognitive impairment prognosis software mean for a hospital's AI review? Plain-language summary.

When a vendor says its software is “FDA authorized,” hospital administrators and nurse leaders still need to know what that covers. A rule published in the Federal Register on November 5, 2026 is a useful example. It places software that estimates how a patient with mild cognitive impairment (MCI) may progress into a regulated category. This post summarizes what the rule says and what a hospital team can ask. It is general information, not legal advice.

What the rule does

According to the Federal Register notice (docket FDA-2026-N-12212, effective November 5, 2026), FDA is classifying “prognostic assessment software of mild cognitive impairment” as a class II device, with special controls. The rule is codified at 21 CFR 882.1454.

The notice describes the device as prescription-only software that combines information from several clinical data sources. It estimates how likely a patient who already has an MCI diagnosis is to progress to more severe cognitive impairment or dementia within a set timeframe.

Why this matters beyond one product

The notice explains that FDA acted on a company’s De Novo request, the pathway for new devices that have no prior classification. FDA found that general controls alone were not enough but that special controls could provide reasonable assurance of safety and effectiveness. It issued its order to that company in January 2024, and this notice writes the classification into the regulations. Because the category now exists, similar future devices can generally use it as a reference and go through the 510(k) process instead of a new De Novo request.

For a hospital, that means more products may arrive under the same label. “Cleared” does not mean “right for our patients.”

What the special controls and limits tell you

The notice lists special controls that cover clinical performance testing and postmarket surveillance, software verification and hazard analysis, human factors testing, and labeling for clinicians and patients. It also states limits: the software is an adjunct, not a standalone diagnostic or prognostic tool, its output should be read with the full clinical picture, and it may not perform as expected for some subpopulations.

Questions a team can ask a vendor, drawn from those points:

  • Which patient groups were the performance data based on, and do they look like ours?
  • Who reviews the output, and how is it explained to patients and families?
  • What happens after go-live: how are errors and complaints tracked?

Key takeaways

  • FDA classified MCI prognosis software as class II with special controls (21 CFR 882.1454), effective November 5, 2026.
  • The software supports clinicians; it is not a standalone diagnostic or prognostic tool.
  • Hospital teams can use the stated limits and controls as a checklist for vendor questions. Confirm specifics with your compliance staff.

This site provides general information for research and education. It is not medical advice and does not replace diagnosis or guidance for any specific patient. It is not legal advice.

This article is part of a series

All series

← Blog